"The past 12 months have been a period of exceptional accomplishment and achievement for Avivagen," he said. "As a Company, we have taken tremendous strides in the development and commercialization of our unique OxC-beta™ technology, an antibiotic-free alternative that promotes health in animals and humans. We believe that both the timing and the value proposition of adopting our technology has never been better."
"New and recurring orders, new applications of our technology and a quickly expanding geographical footprint are a growing cache of proof that our OxC-beta technology is making significant inroads into the world's biggest markets," Anthony stated.
Along with upgrading to the OTCQB Venture Market in the U.S., Anthony reported that Avivagen made strides advancing its proprietary OxC-beta in the livestock and companion animals markets in 2019. For one, the life sciences company obtained regulatory approval of OxC-beta Livestock in four additional countries.
In the Asia Pacific region, Avivagen initiated product sales in Taiwan and Malaysia and received approval to sell in Australia and New Zealand. In China, the company signed an agreement with COFCO BIOTECH, a government-owned corporation, to help get OxC-beta Livestock registered for use in poultry feed. "This follows the decision by the Chinese government to ban all AGPs (Antibiotics as Growth Promoters) by July 2020," Anthony noted. Also, Avivagen landed a new distribution partner in the Philippines.
In North America, the company attained Self-Affirmed GRAS, or generally recognized as safe, status and partnered with CSA Animal Services in the U.S. Subsequently, Mexico approved the sale of OxC-beta Livestock there.
With respect to the companion animals market, Avivagen entered a joint venture for its product, Vivamune, with Mimi's Rock, an online marketer of human health and wellness brands. Rebranded as Dr. Tobias Dog Chews, the canine supplement will be sold on Amazon and the proprietary website, drtobias.com.
Anthony indicated that Avivagen will continue its three-pronged approach to growth. It will keep increasing sales, forming additional partnerships and seeking further country regulatory approvals.
"We expect 2020 to create new revenue opportunities for the company and even greater value for our shareholders," he added.
Read what other experts are saying about:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.